TY - JOUR T1 - District level correlates of COVID-19 pandemic in India JF - medRxiv DO - 10.1101/2020.10.08.20208447 SP - 2020.10.08.20208447 AU - Vandana Tamrakar AU - Ankita Srivastava AU - Mukesh C. Parmar AU - Sudheer Kumar Shukla AU - Shewli Shabnam AU - Bandita Boro AU - Apala Saha AU - Benjamin Debbarma AU - Nandita Saikia Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/11/2020.10.08.20208447.abstract N2 - Background The number of patients with coronavirus infection (COVID-19) has amplified in India. Understanding the district level correlates of the COVID-19 infection ratio (IR) is therefore essential for formulating policies and intervention.Objectives The present study examines the association between socio-economic and demographic characteristics of India’s population and the COVID-19 infection ratio at district level…Data and Methods Using crowdsourced data on the COVID-19 prevalence rate, we analyzed state and district level variation in India from March 14 to July 31 2020. We identified hotspot and cold spot districts for COVID-19 cases and infection ratio. We have also carried out a regression analysis to highlight the district level demographic, socio-economic, infrastructure, and health-related correlates of the COVID-19 infection ratio.Results The results showed that the IR is 42.38 per one hundred thousand population in India. The highest IR was observed in Andhra Pradesh (145.0), followed by Maharashtra (123.6), and was the lowest in Chhattisgarh (10.1). About 80 per cent of infected cases, and 90 per cent of deaths were observed in nine Indian states (Tamil Nadu, Andhra Pradesh, Telangana, Karnataka, Maharashtra, Delhi, Uttar Pradesh, West Bengal, and Gujarat). Moreover, we observed COVID-19 cold-spots in central, northern, western, and north-eastern regions of India. Out of 736 districts, six metropolitan cities (Mumbai, Chennai, Thane, Pune, Bengaluru, and Hyderabad) emerged as the major hotspots in India, containing around 30 per cent of confirmed total COVID-19 cases in the country. Simultaneously, parts of the Konkan coast in Maharashtra, parts of Delhi, the southern part of Tamil Nadu, the northern part of Jammu & Kashmir were identified as hotspots of COVID-19 infection. Moran’s-I value of 0.333showed a positive spatial clusteringlevel in the COVID-19 IR case over neighboring districts. Our regression analysis found that district-level population density (β: 0.05, CI:004-0.06), the percent of urban population (β:3.08, CI: 1.05-5.11), percent of Scheduled Caste Population (β: 3.92, CI: 0.12-7.72),and district-level testing ratio (β: 0.03, CI: 0.01-0.04) are positively associated with the prevalence of COVID-19.Conclusion COVID-19 cases were heavily concentrated in 9 states of India. Several demographic, socio-economic, and health-related variables are correlated with COVID-19 prevalence rate. However, after adjusting the role of socio-economic and health-related factors, the COVID-19 infection rate was found to be more rampant in districts with a higher population density, a higher percentage of the urban population, and a higher percentage of deprived castes and with a higher level of testing ratio. The identified hotspots and correlates in this study give crucial information for policy discourse.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is not a clinical study. It is done in the basis of publicly available data.Clinical Protocols https://www.covid19india.org/ Funding StatementNo funding information is applicable.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data is publicly availableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is publicly available. https://www.covid19india.org/ ER -